PCN383 COST-EFFECTIVENES ANALYSIS OF AVELUMAB AS SECOND-LINE TREATMENT FOR PATIENTS WITH METASTATIC MERKEL CELL CARCINOMA IN RUSSIA
Nov 1, 2019, 00:00 AM
10.1016/j.jval.2019.09.578
https://www.valueinhealthjournal.com/article/S1098-3015(19)32956-0/fulltext
Section Title :
Section Order :
10496
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)32956-0&doi=10.1016/j.jval.2019.09.578